Industry News

On Sept. 27, 2019, Bayer sent the following letter聽and pharmacovigilance summary聽to HFA and NHF. Bayer submitted these materials in response to a joint HFA-NHF letter, part of the ongoing dialog over Bayer鈥檚 distribution and subsequent recall of two lots of improperly labeled, expired clotting factor.

Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, including your possible exposure to recalled product, please consult your physician.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.